Ann: PAR REPORTS PAIN REDUCTION IN OA PATIENTS, page-5

well results were obviously worse for this 25 patients than the first 125 on average (as it reduced the average).... but, take out patients 76-100 which had ~ 60% pain reduction and this is the same positive results as the first 75 patients reported on.....

sure, there will likely be a batch or two that end up being worse results than the average....as there will be a batch or two that are better than the average....

perhaps a few disappointed that this wasn't ~60% pain reduction when it appears the results were based on the similar 6 week patient timeframe.... this afterall, is what they indicated had led to the last 25 patients being at 60%....

but considering the two quotes below... there is nothing at all worng with 50%....

"The pain reducing effects of iPPS are considered significantly superior than the typical 15% pain reduction scores reported for opioid treatments for chronic pain in OA of the knee and hip." (all while a massive opioid addiction problem in the USA, and well and truly understood by the FDA)

“Clinically meaningful reduction of chronic pain has been defined to be between 25-30% pain reduction”



i wonder if there is a few holders that made the same mistake as me and looked at the forecast cash spend for the sept quarter and the june cash balance and thought a CR was imminent....

i hadn't done my research and it wasn't until i'd read @Dungiven 's post below that i realised they had cash receipts coming in to see them through the trials....so no need for a raise yet...

https://hotcopper.com.au/threads/tim-boreham-whats-next-for-par.4450643/?post_id=35789696

there was $1mil in options conversion money and a $2m R&D tax incentive due in Sept...